Dr. Dominic King-Smith
President and CEO
Enzen Therapeutics, Inc
Dr. Dominic King-Smith has worked in the pharmaceutical industry for the last 20 years, mainly in the field of topical prescription drugs. He helped establish fqubed, a company that pioneered the use of high throughput experimentation in the field of formulation development of skin-applied products. fqubed was acquired by Nuvo Research in 2005.
At Nuvo, Dominic served in executive positions in new product and strategic planning. He played a key role in developing Pennsaid 2%, until recently the top-selling topical product on the US market. Subsequently, he served as Crescita’s VP Corporate Development where he concluded key out licensing transactions for the company with commercialization partners in the US and Europe. In 2021 he was recruited by Mumbai-based Encube Ethicals to serve as EnZen’s CEO where he leads the development of a portfolio of products for the treatment of rare diseases based on inhibition of kallikrein 5. Dominic holds BA and PhD degrees from Cambridge University and is named as an inventor on 20 issued US patents. He started his career as a theoretical physicist, a field where he is best known for his foundational contributions to the quantum theory of polarization.